We hypothesized that intraoperative eRFA extends the "final" tumor-free margin, decreases local recurrence, and maintains cosmesis without the need for radiation (XRT).<h4>Patients and methods</h4>Patients with unifocal ER+PR+HER2- or DCIS tumors less than or equal to 3 cm with clinically negative nodes were included. This evidence concerns the gene ERBB2 and neoplasm.